Physician profile
Phillip Haggerty
NPI 1902820954
$1,833.38
in general payments reported to CMS, 2019-2025
25 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $339 · 2021: $193 · 2022: $68.14 · 2023: $505 · 2024: $206 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $462.18 | 2020-2023 | Senza |
| Collegium Pharmaceutical, INC. | $382.37 | 2019-2024 | Xtampza |
| Scilex Pharmaceuticals INC. | $146.85 | 2022-2025 | Ztlido |
| Amgen INC. | $135.61 | 2019 | |
| Painteq LLC | $110.46 | 2022-2023 | Painteq |
| Abbott Laboratories | $82.57 | 2019-2025 | Eterna, Immunalysis Corporation |
| Boston Scientific Corporation | $75.26 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Ipsen Biopharmaceuticals, INC | $58.23 | 2024 | Dysport |
| Tersera Therapeutics LLC | $39.74 | 2022-2025 | Prialt |
| Pfizer INC. | $36.06 | 2019 | |
| Redhill Biopharma INC. | $35.05 | 2020 | |
| Shionogi INC | $32.48 | 2019 | |
| Flowonix Medical Incorporated | $24.55 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $23.69 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $23.25 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $22.12 | 2025 | Acthar |
| Pacira Therapeutics, INC. | $20.79 | 2021 | |
| Vertos Medical, INC. | $20.36 | 2024 | Mild Device Kit |
| Virtus Pharmaceuticals LLC | $16.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.44 | 2022 | |
| Medtronic USA, INC. | $15.06 | 2019 | |
| Medtronic, INC. | $14.82 | 2021 | |
| Sentynl Therapeutics, INC. | $14.06 | 2019 | |
| Daiichi Sankyo INC. | $13.37 | 2019 | |
| Zyla Life Sciences, INC. | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Haggerty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.